Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer.

泛亚适应的 ESMO 临床实践指南的诊断 ，转移性结直肠癌患者的治疗和随访。

• 影响指数: 6.883
• 发表时间: 2023 Jun 24
• 来源期刊: ESMO Open
• DOI: 10.1016/j.esmoop.2023.101558
• PMID: 37236086
• 文章类型: Practice Guideline
• 作者列表: Yoshino T,Cervantes A,Bando H,Martinelli E,Oki E,Xu RH,Mulansari NA,Govind Babu K,Lee MA,Tan CK,Cornelio G,Chong DQ,Chen LT,Tanasanvimon S,Prasongsook N,Yeh KH,Chua C,Sacdalan MD,Sow Jenson WJ,Kim ST,Chacko RT,Syaiful RA,Zhang SZ,Curigliano G,Mishima S,Nakamura Y,Ebi H,Sunakawa Y,Takahashi M,Baba E,Peters S,Ishioka C,Pentheroudakis G

关键词: ESMO; Pan-Asian; guidelines; metastatic colorectal cancer; treatment

Mesh: Humans; Follow-Up Studies; Asia; Colonic Neoplasms; Societies, Medical; Medical Oncology

Abstract

The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer (mCRC), published in late 2022, were adapted in December 2022, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with mCRC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with mCRC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian countries. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with mCRC across the different countries of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation, coupled with a disparity in the drug approvals and reimbursement strategies, between the different countries.

摘要

欧洲医学肿瘤学会（ESMO）诊断的临床实践指南，转移性结直肠癌（mCRC）患者的治疗和随访，于2022年底发布，根据先前建立的标准方法，于2022年12月进行了调整，制定泛亚适应（PAGA）ESMO共识指南，以管理亚洲mCRC患者。本手稿中提出的适应指南代表了代表中国肿瘤学会（CSCO）的亚洲专家小组在治疗mCRC患者方面达成的共识意见。印度尼西亚(ISHMO)，印度(ISMPO),日本(JSMO),韩国(KSMO),马来西亚(MOS),菲律宾（PSMO）新加坡(SSO),台湾（TOS）和泰国（TSCO），由ESMO和日本医学肿瘤学会（JSMO）协调。投票基于科学证据，独立于当前的治疗实践，不同亚洲国家的药物准入限制和报销决定。后者在手稿中单独讨论。目的是为亚洲不同国家的mCRC患者管理的优化和协调提供指导，借鉴西方和亚洲试验提供的证据，在尊重筛查实践差异的同时，分子谱分析和年龄和阶段，再加上药物批准和报销策略的差异，在不同国家之间。